Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125439062 | 12543906 | 2 | F | 20160629 | 20160711 | 20160919 | EXP | US-ALVOGEN-2016-ALVOGEN-025864 | ALVOGEN | EILERS B, ALBERS E, LAW Y, MIKE MCMULLAN D, SHAW D, KEMNA M. POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME AFTER PEDIATRIC HEART TRANSPLANTATION: INCREASED RISK FOR CHILDREN WITH PREEXISTING GLENN/FONTAN PHYSIOLOGY.PEDIATRIC TRANSPLANTATION. 2016; 20(4):552-558 | 9.00 | YR | M | Y | 0.00000 | 20160919 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125439062 | 12543906 | 1 | PS | LEVETIRACETAM. | LEVETIRACETAM | 1 | U | 90906 | |||||||||||
| 125439062 | 12543906 | 2 | SS | LORAZEPAM. | LORAZEPAM | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125439062 | 12543906 | 1 | Product used for unknown indication |
| 125439062 | 12543906 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125439062 | 12543906 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125439062 | 12543906 | Posterior reversible encephalopathy syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |